Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Oct 10 - Oct 15
The FDA approved tesamorelin in 2010 to treat abdominal fat in adults with HIV-associated lipodystrophy
But, semaglutide repeatedly showed its effectiveness in causing weight loss in patients with or without diabetes by reducing appetite and caloric intake
Retrieved 2026-01-08
Possible Side Effects Mild digestive discomfort with oral supplements Skin rashes in rare cases Kidney strain with very high doses taken long-term Risk of infection or adverse reaction if IV is administered without proper sterile protocol Who Should Avoid It Pregnant or breastfeeding women People with asthma (high doses may trigger bronchospasm) Anyone with a known sensitivity to sulphur compounds Those with pre-existing kidney or liver conditions The risks are largely manageable under proper supervision
Talk with your insurer or pharmacy benefit manager: Is Wegovy, Zepbound, or your prescribed GLP-1 on the drug formulary for weight management
